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1. Introduction
Due to their advanced optical properties, plasmonic nanoparti-
cles are receiving an increased interest for photothermal therapy 
(PTT). This is evident from the rise in number of publications 
in these two fields within the last two decades (Figure 1). One 
Nanomedicine approaches based on targeted delivery of nanoparticles have 
enormous therapeutic potential. For this to succeed, the nanoparticles, 
possibly functionalized or activatable by lasers, need to reach their target in 
the organism and preferably accumulate at this target. However, administra-
tion of nanoparticles in vivo results in rapid clearance of the particles by the 
immune system, thus preventing the nanomedicine in reaching its target. 
Passivation by polymer coatings has provided some success, but has not 
been sufficient to transform nanomedicine into an effective therapy. Recently, 
a new approach has been adopted which utilizes native cellular membranes 
for coating of nanoparticles. Motivated by the signaling and recognition capa-
bilities of natural cell membranes, it is now feasible to produce nanoparticles 
with both immune evasive and tumor targeting abilities. Circulation times 
are dramatically enhanced by natural membrane coatings allowing signifi-
cant increase in the passive accumulation by the enhanced permeability and 
retention effect. Membrane coating of nanoparticles provides a promising 
new development for advanced nanoparticle photothermal therapy (PTT). 
Here, the recent advances and challenges facing this new type of nanopar-
ticle technology, bridging advanced optical properties with bio-compatibility, 
are reviewed with a focus on membrane coating of plasmonic nanoparticles 
which has shown great promise in PTT.
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key challenge, however, related to the use 
of nanoparticles for therapeutic purposes, 
is the lack of efficient methods to up-con-
centrate the particles at the site for thera-
peutic action, for example, in a tumor.[1] 
Upon successful targeting and up-con-
centration, much more efficient drugs 
could be used than if the nanoparticle 
loaded with drugs is distributed randomly 
throughout the entire organism. Also, 
lower dosages would be needed to achieve 
satisfactory levels of drugs at the desired 
site of delivery.[2] Furthermore, biopharma-
ceutical drugs such as enzymes, peptides, 
and antibodies are becoming more and 
more popular as therapeutic agents. How-
ever, biopharmaceuticals are large mole-
cules (in the kDa range), which impose 
challenges in the delivery step due to low 
permeability through biological barrier 
interfaces such as cell membranes, mucus 
associated barriers, as well as the skin.[3]
These factors introduce a need for 
improved integration of drugs in delivery 
agents, targeting to specific action sites, 
and a means of cargo-release either 
through outer stimuli, for example, triggered by laser light, or 
by an encoded “unlock and release mechanism” that is acti-
vated at the appropriate location inside the organism.
Nanocarriers, for instance in the form of metallic nano-
particles, exhibit several attractive features such as easy 
functionalization with targeting molecules into tumors and 
can exhibit intrinsic physical properties like plasmonic absorp-
tion.[3,4] One of the key features to take advantage of using 
nanoparticles (NPs) is the enhanced permeability and retention 
(EPR) effect, which is a well-described phenomenon in cancer 
tissue, but also present in tissue with increased vascular perme-
ability, for example, at sites of infection.[5] Nanoparticles with 
sizes larger than 10 nm are significantly larger than molecular 
drugs and are therefore not exposed to renal clearance and 
urinal excretion. Hence, certain size intervals of nanoparticles 
can extravasate through leaky vasculature, as often present in 
tumors, and hence the EPR effect effectively causes a localized 
delivery of drugs in the tumor, this is illustrated in Figure 2.[6] 
However, clinical trials have failed at exploiting the EPR effect 
successfully, making targeting ever so relevant.[7]
NPs can be either functionalized or engineered into having 
desirable features, that is, prolonging circulation time in the 
blood stream, incorporation of cargo molecules, or being 
activatable by lasers for a controlled release of drugs.[8–11]  
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Additionally, NPs such as FDA-approved poly(lactic-co-gly-
colic acid) (PLGA) and poly(caprolactone) (PCL) particles are 
biodegradable and have been studied as drug cargo vehicles.[9]
Inorganic NPs, especially gold NPs (AuNPs), have a great 
potential due to several features: First, the ease of surface 
modification with biomolecules through thiol bonds allows for 
specific targeting without involving complex chemistry.[12,13] 
Second, the recent developments in inorganic NP synthesis 
allows for fabrication of a wide array of NPs with different 
sizes, shapes, and surface charge.[4,14,15] The variety in NP 
shapes which can be fabricated today opens up interesting 
applications within thermoplasmonics which relies on the plas-
monic properties of AuNPs. Plasmonic heating produced by 
irradiation of metallic NPs makes them feasible as remotely 
controllable nanoheaters[16] for thermoplasmonic treatment,[4,17] 
imaging purposes, as well as vehicles for controlled release of 
cargo from the particle itself.[8,11,18] AuNPs are able to absorb the 
energy from a focused light source and convert it into a very 
localized heating.[15] The ability to tune the absorption spectrum 
of AuNPs is very promising in nanomedicinal treatments as the 
particles’ absorbance of light can be shifted into the biological 
transparency window (BTW) which exists in the near-infrared 
(NIR) regime. This can be done by altering the shape, size, or 
composition of the NPs, thereby taking advantage of the light 
as a nearly noninvasive tool, which inflicts only little (possibly 
non-essential) damage on healthy tissue.[19]
These factors make plasmonic NPs promising candidates 
in the search for novel therapies of diseases such as cancer.[20] 
Considerable efforts have been made to design NP-based 
drug delivery systems for up-concentrating NPs at the desired 
therapeutic site. However, a careful review from 2016 going 
through 10 years of literature on this topic demonstrated that 
on average in literature, only 0.7% of the administered nano-
particles were found to be delivered at tumor sites and no “killer 
method” was reported.[1] Hence, upscaling from mice to human 
levels still poses a major challenge, and to this end, even more 
advanced NPs bridging optics and biology need to be developed.
2. Nanoparticles Relevant for Membrane Coating 
and PTT
Today, there is a vast array of commercially available NPs in a bio-
compatible quality to be used for nanomedicinal purposes; exam-
ples are discussed in Figure  3. The warehouse of NPs ranges 
from lipid based particles such as liposomes and micelles, poly-
meric particles, and polymer conjugates such as poly(ethylene 
glycol) (PEG)-based particles and PLGA encapsulating drugs to 
inorganic particles like AuNPs, and organic particles such as 
carbon nanotubes and dendrimers.[9,21–23] In the following, we 
devote our attention to plasmonic NPs and describe the charac-
teristic optical properties of this class of particles and motivate 
their use as membrane camouflaged nanostructures.
2.1. Plasmonic Nanoparticles
The first known use of plasmonic NPs is in ancient art such 
as the Roman’s Lycurgus cup from the fourth century, where 
the dichroism is evident from holding a light source inside or 
outside the cup. The reason for this phenomenon was found 
in 1990 to be due to the presence of metallic particles (66.2% 
silver, 31.2% gold, and 2.6% copper) in the nanometer range 
inside the glass.[24] The amazing colors found in the cup are 
due to scattering and absorption properties from the diverse 
metallic NPs in different size regimes.
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A key advantage of plasmonic NPs is that they can be acti-
vated by external laser light. Hence, it is possible to control NP 
heating and thereby PTT or release of cargo with high precision 
in time and space. The light-to-heat conversion by plasmonic 
nanoparticles, when irradiated by electromagnetic waves, peaks 
when resonant light optimally excites the electronic oscillations 
within the NP (Figure  3A); heat is generated from so called 
Joule heating,[25] which originates from friction between the 
electrons and the metallic lattice.
The interaction between light and a plasmonic NP will 
depend on the composition, size, and geometry of the NP 
and on its environment.[4,26] This interaction can be described 
through the extinction cross section (Cext), which is defined as 
the sum of scattering and absorption cross sections. The extinc-
tion cross section of a particle embedded in a dielectric medium 
with permittivity em and irradiated at a given wavelength λ can 
be described by the optical theorem[27]
Im( )ext κ α=C  (1)
where the wavenumber is 2 /κ pi ε λ= m  and α is the polariz-
ability of the particle. When the size of the NP is much smaller 
than the wavelength, the scattering can be neglected and we 
get Cabs ∼ κIm(α). For small particle sizes, the polarizability is 
given by
3
( )
( )
α
ε ω ε
ε ω φε=
−
+
V m
m  
(2)
Here, V is the volume of the particle, e is the dielectric per-
mittivity of the particle at the given frequency ω, em is the die-
lectric permittivity of the medium, and φ is a shape dependent 
parameter,[28] which for a sphere equals 2. The resonance is 
found when the absorption and scattering cross sections are at 
their maximum. The resonance wavelength is also dependent 
on the shape-dependent parameter, φ, and can be found as[29] 
maxλ λ ε φε= +p ib m , where eib is the electronic interband 
transition contribution and λp is the plasmon wavelength in the 
bulk material.
In practice, this means that light absorption and scattering 
can, through this mechanism, exhibit a fine sensitivity to small 
changes in the shape of a NP, as for instance when modulating 
the aspect ratio of gold nanorods[4,30] or varying the thickness of 
a gold layer in gold nanoshells (AuNSs)[4] (see Figure 3C). On 
the other hand, increasing the size of a spherical AuNP does 
not lead to a significant shift in the resonance, although there 
is a substantial increase of absorption with size as shown by the 
calculated result in Figure 3B.
The extreme size, composition, and shape-dependent char-
acteristics of the optical absorption outlined above is a major 
reason for the significant attention devoted to plasmonic NPs 
in literature, as evident from Figure 1. It is of particular interest 
to tune the absorption to the NIR because this allows for 
external laser-induced activation of plasmonic NPs within living 
specimens for heat production with high precision in time and 
space without essential damage to the surrounding tissue.
2.1.1. Gold Nanoparticles
Among the huge variety of currently available plasmonic NPs, 
AuNPs have received much attention due to their low cyto-
toxicity and commercial availability in a reproducible and bio-
compatible quality and in a variety of sizes,[4,14] (see overview in 
Figure 3D).
Irradiation of gold nanoparticles has been extensively used 
in photothermal applications. The generation of heat originates 
from the absorption of optical energy, followed by a dissipation 
of heat into the medium surrounding the nanostructure.[31] 
Equilibration of the heat distribution in the surrounding 
medium is achieved within ≈ 100 ns[32] with the radial exten-
sion of the elevated thermal profile away from its surface being 
of the same magnitude as the size of the plasmonic particle.[33]
Adv. Optical Mater. 2020, 2000616
Figure 1. A) Plot of number of publications within the topics “plasmonic nanoparticle(s)” and “photothermal therapy” showing the increase in sci-
entific papers available from the Web of Science database in late March 2020. B) Research area-distribution of papers within the topic “plasmonic 
nanoparticles” pointing to the significance in fields such as physics, biophysics, and material science. Data show the 12 most prevalent research fields.
Figure 2. Schematic illustration of the enhanced permeability and reten-
tion effect. This effect helps up-concentration of drug-loaded nanoparti-
cles of certain sizes by passive targeting. The effect is strongly enhanced 
by prolonged circulation times in the bloodstream, which can be achieved 
by various camouflage coatings.
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By solving the heat transfer equation,[34] the temperature 
increase in the vicinity of an irradiated NP can be calculated 
through the relation[16]
( )
3
3
abs∆ =T D
R I
DKV
C
 
(3)
Here, Cabs is the absorption cross section, mentioned above, 
which is defined as the ratio between the power absorbed by 
the particles and total incoming laser intensity (power per 
area). Cabs can be found using Mie theory. R is the radius of 
the particle, V is the particle volume, I is the intensity on the 
particle, D is the distance from the center of the particle, and K 
is the thermal conductivity of the medium in which the particle 
is suspended.
Using Equation (3), the heating of individual particles can be 
calculated. The temperature increase is directly proportional to 
Cabs and Figure 3B shows how Cabs depends on particle diam-
eter for solid spherical AuNPs in water; the color code shows 
the NP’s temperature increase if irradiated by a laser of wave-
length of λ = 808 nm with a power density of 9 10 W cm6 2× − . 
Figure 3C shows how the absorption cross section of different 
NPs with resonance in the NIR depends on their shape and 
composition while irradiated with a laser of wavelength of 
λ = 808 nm. As suggested in ref.  [17], the use of this specific 
wavelength allows for heating of AuNPs embedded within 
tissue while avoiding damage to the surrounding healthy 
tissue. We note that Equation (3) describes heating of a single 
nanoparticle; however, photothermal therapy is most often per-
formed using particle concentrations exceeding 109 NPs mL-1; 
under such conditions, collective heating effects from neigh-
bouring NPs significantly alter the absorption,[35] hence, lower 
laser powers are needed to achieve a specific temperature than 
predicted by Equation (3).
Experimental measurements of heating from individual 
plasmonic nanoparticles have been carried out using nano-
thermometry.[16,36] Such measurements allow for an experi-
mental determination of Cabs by using Equation (3), whereby 
the optimal nanostructure for a photothermal application can 
be identified. It was observed that at a distance corresponding 
to the particle’s radius away from the particle’s surface, the 
temperature increase drops significantly (by 30 40≈ − %). This 
is important to take into consideration since collective effects 
giving rise to bulk heating can only be achieved when the 
heating distributions from individual nanoparticles have suffi-
cient overlap.[35,37]
Due to the large diversity in commercially available plas-
monic NPs, including AuNPs, AuNSs, nanomatryoshkas, 
nanostars, nanorods, and many more,[4] it is now possible to 
choose NPs with high absorption cross section at practically 
any wavelength. The summary in Figure 3D gives an overview 
of the different characteristics for several relevant plasmonic 
gold nanoparticles.
One of the key features of metallic NPs is the high surface-
to-volume ratio. This allows for adding a high number of func-
tionalization molecules to the particles per volume. The ease 
of functionalization of AuNPs, due to a favorable interaction 
between gold and the sulfur in thiols, has led to a multitude 
of added molecules such as various drugs,[40,41] miRNA[11] 
and siRNA,[18] DNA,[42] peptides,[43] and “stealth molecules” 
Adv. Optical Mater. 2020, 2000616
Figure 3. Plasmonic properties of metallic nanoparticles depend on their size and shape. A) Illustration of the interaction between the electric field 
from electromagnetic radiation and the conduction electrons in a metallic NP. B) The absorption cross section at λ = 808 nm as a function of particle 
diameter for a spherical and solid AuNP using an intensity of 9 × 106 W cm-2. The temperature increase at the surface of the particle is visualized 
by the colorbar. C) Absorption coefficients for different types of irradiated NPs at λ = 808 nm: Spherical and solid AuNPs with d = 100 nm; AuNS 
with dinner = 80 nm and dshell = 15 nm; gold nano-rods (AuNRs) with length l =120 nm and width w = 30 nm; gold nanomatryoshkas (AuNMs)[38] with 
dinner = 29 nm, dintermediate = 10 nm, and dshell = 13 nm; gold nano-cubes (AuNCs)[39] with l = 100 nm, wallthickness = 10 nm, and cornerholediameter = 10 nm; 
gold nanostars (AuNSt) with dcore = 80 nm, ltip = 25 nm, and tipdiameter = 5 nm. Numbers are taken from Ref. [4]. D) Overview of advantages and 
disadvantages of a selection of gold nanoparticles relevant for photothemal therapy.
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such as PEG molecules.[23] A challenge to consider if using 
metallic nanoparticles in vivo is the tendency to agglomerate 
when the particles are introduced into a saline solution due 
to the decrease in Debye length facilitated by the ions in solu-
tion.[13,44] Introduction into the blood stream will expose par-
ticles to a milieu containing salts, amino acids, enzymes etc., 
thus exposing the particles to a variety of destabilizing factors 
that may increase agglomeration. Agglomeration, however, will 
increase the local concentration of the particles which may be 
beneficial for reaching higher temperature upon laser irradia-
tion due to collective effects.[35]
2.1.2. Other Nanoparticles
Several inorganic particles made from materials like Ag, Pt, Pd, 
Li, Na, Al, or other alternative plasmonic materials are currently 
being tested for their photothermal properties and do hold 
potential for future use with NIR light.[45–47]
Copper sulfide nanoparticles (CuSNPs) are known to exhibit 
a significant absorption in the NIR spectrum.[48] However, the 
reason for the absorption is not found in the plasmonic proper-
ties, but rather in energy band–band transitions. An increase 
in temperature was observed when an aqueous solution of 
CuSNPs was irradiated with a NIR laser (808 nm) over the 
course of 15 min.[48] In the same study, it was shown that cell 
viability decreased significantly after laser irradiation in HeLa 
cells. Furthermore, the cytotoxicity was investigated and com-
pared to AuNPs and CuCl2, indicating a lower cytotoxic effect 
from the CuSNPs. The small drawback on the CuSNPs is 
the inability to tune the absorbance peak. Hence, the peak is 
located at ≈900 nm for all sizes, but it is evident that the absorp-
tion power increases with particle size.
In recent years, iron-oxide nanoparticles (ION)s such as 
Fe3O4 have received much attention in fields ranging from bio-
medicine and healthcare to energy, agriculture, and construc-
tion.[49] The obvious advantage of using IONs in biomedicine as 
an alternative to AuNPs is their low production costs and their 
magnetic properties. Furthermore, the dual functionality of the 
particles (i.e., magnetic properties along with plasmonic prop-
erties) makes these particles a versatile tool in both imaging 
and PTT. Hence, they can be used as contrast agents with 
magnetic resonance imaging (MRI), and using an alternating 
magnetic field, heat can be generated, which can be utilized for 
hyperthermia as well as drug delivery. Furthermore, the par-
ticles are biocompatible due to the fact that iron is a nutrient 
metabolized in the body.[49,50] Recently, the photothermal prop-
erties of IONs have been given more attention.[51–53] Although 
the plasmonic properties of IONs are not as pronounced as 
their gold counterpart, they have been shown to increase the 
temperature of their surroundings following treatment with an 
NIR (808 nm) laser.[51] The plasmonic properties of IONs were 
further studied by Shen et al.,[52] who showed that the interac-
tion with light is greatly enhanced when the particles cluster 
together. It was found that the absorption of the clustered par-
ticles was significantly higher than the single particle assay and 
a 3.6-fold increase in the absorption at 808 nm was found. Fur-
thermore, cell viability was affected by the clustering of parti-
cles, following NIR laser irradiation, and cell death was more 
pronounced for the clustered particles. The use of IONs in PTT 
is complicated by the fact that particles tend to aggregate in 
saline solutions which might increase the photothermal effect 
in the biological transparency window, but might reduce accu-
mulation by the EPR effect (see Figure 2), due to the large size 
of the aggregates. Clustering of the Fe3O4 NPs is also expected 
to happen once they have been administered in vivo and should 
be resolved by using efficient coatings.
One drawback of using inorganic NPs in vivo is the poten-
tial problem of upconcentration in vital organs such as the 
liver and spleen[54] (see also Figure  6). To overcome this chal-
lenge, biomembrane-coated polymeric nanoparticles have been 
explored for drug delivery purposes. However, as these particles 
do no exhibit the optical or magnetic properties needed for PTT 
and special imaging purposes (i.e., MRI), these particle types 
are not covered here in detail and we recommend refs. [55–67] 
to the interested reader.
3. Membrane Coating of Plasmonic Nanoparticles
Most bio-incompatible NPs are recognized by the immune 
system as foreign objects and hence become excreted from the 
blood stream within a few hours and accumulate in the liver 
and spleen. Therefore, there is a need for a stealth or biomim-
icking approach which will be essential for having the particles 
circulating in the bloodstream long enough for a significant 
amount to reach the desired destination.
For many years, functionalization with PEG molecules 
(PEGylation) has been the state-of-the-art method for pro-
longing NP circulation time in the body, thus facilitating pas-
sive targeting.[2,3] PEGylation of particles forms a hydrated 
polymeric brush layer which neatly prevents protein adsorp-
tion and opsonization.[68] Furthermore, PEGylation lowers the 
uptake-rate by the organs (liver and spleen), has low intrinsic 
toxicity, and is soluble in water, which also increase drug solu-
bility in water. To further solidify the importance of PEG in bio-
logical applications, the resulting steric hindrance contributes 
to a lowering of any charge-induced interactions with the body 
or other particles due to a decrease of zeta-potentials.[69] The 
“stealth” properties of PEGylation has been well established 
and several PEG-coated particles are already FDA approved or 
in clinical trials.[69–71] As an example, coating of AuNPs with 
PEG molecules has been shown to prolong circulation time in 
rats where 18% of the AuNPs was still found circulating in the 
blood after 24 h (compared to 0.1% for particles coated with the 
colloidal stability enhancing molecule bis(p-sulfonatophenyl) 
phenylphosphine).[72]
Even though PEGylation of particles has been used for 
decades, the polymer has proved to have some flaws. For 
example, PEG derivatives have been investigated with respect 
to two different cell lines where the findings suggest a mode-
rate cytotoxicity for certain PEG derivatives when introduced 
to mouse fibroblasts (L929).[73] Other studies have found that 
anti-PEG antibodies are expressed in some healthy individ-
uals[74] and PEG has a tendency to induce blood clotting due 
to non-specific interactions between blood and PEG polymers. 
Also, PEG-containing liposomes have been found to be able 
to induce hyper-sensitivity reactions which might provoke 
Adv. Optical Mater. 2020, 2000616
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an anaphylactic shock in a worst case scenario. For a thor-
ough review on PEGylation, we encourage the reader to read 
ref. [69].
Several polymeric alternatives to PEG have been proposed, 
many of which show the same efficacy as PEG.[23] Polyvinylpyr-
rolidone (PVP) and polyoxazolines (POX) are two types of poly-
mers that have been tested as alternatives to PEG. For example, 
AuNPs have been coated with oligo(2-ethyl-2-oxazoline), a POX 
polymer which can be modified to bind to a specific particle 
surface.[75] Furthermore, a peptide sequence was added for rec-
ognition of a specific β1 integrin, overexpressed in A549 lung 
cancer cells. These POX-coated AuNPs are promising, espe-
cially for cancer imaging purposes. PVP has been used to func-
tionalize AuNPs along with doxorubicin (DOX) for A549 lung 
cancer cell apoptosis,[76] and addition of PVP to IONs showed 
low cytotoxicity and low aggregation in water and was used as 
an MRI contrast agent.[77] It should be noted, however, that PVP 
has been reported to have trouble with biodegradability and 
immunogenicity.[78] Several other polymeric stealth coatings 
have been proposed, for example, polyglycerols, polyacrylamides, 
polyaminoacids, and polysaccharides.
Although PEG and other types of polymers have provided sig-
nificant progress to the delivery part of NPs, there is an urgent 
need to find new strategies to further increase circulation 
times with preferentially biomimetic and nontoxic materials. 
An interesting approach is to exploit nature’s own fabrication 
of interfaces, namely the cellular plasma membrane, which we 
review in the following section.
3.1. Biomembrane Mimicking
In recent years, biomimetic approaches to prolonging the circu-
lation of nanotherapeutics have been suggested. These include 
coating different types of NPs with cell-derived membranes like 
red blood cells (RBC),[55,79] white blood cells (WBC),[62,80] cancer 
cells,[81] stem cells,[82,83] or blood platelets[79] as well as func-
tionalization with well known “do-not-eat-me”-signal activating 
molecules like CD47.[68,84] This concept is schematically illus-
trated in Figure 4, where nanoparticles are coated with different 
types of cell membranes followed by injection into the blood-
stream and subsequent up-concentration in the tumor. Further-
more, membranes from bacteria have been studied as a coat 
and could potentially help in the development of antibacterial 
vaccines when used as a coating of AuNPs.[85] The motivation 
for using membrane coating to camouflage NPs is summarized 
in Figure 5, which shows a promising and improved delivery 
and therapeutic effect of a number of different types of mem-
brane-coated NPs tested in vivo.
In the following section, we focus on the coating of plas-
monic NPs using mammalian cell types for treatment of 
diseases such as cancer as well as for enhancing imaging 
conditions. NP coatings by plasma membranes from dif-
ferent cell types are outlined and the specific advantages and 
dis advantages associated with the respective cell type are dis-
cussed. Also, there are descriptions of the different methods 
used for extracting cellular plasma membranes and discussion 
of subsequent coating strategies.
Adv. Optical Mater. 2020, 2000616
Figure 4. Schematic showing the sequence of membrane coating, particle injection, EPR, and endocytosis into tumor cells. 1) Membranes from cells 
of interest are isolated through various methods. 2) The isolated membranes are then mixed with the NPs and extruded through a nanometer sized 
filter in order to facilitate functionalization and membrane coating of the particles. Validation of successful membrane coating can be performed using 
various techniques like dynamic light scattering or transmission electron microscopy to detect size changes caused by addition of a coating. 3) Intra-
venous injection of the functionalized and membrane-coated particles facilitate high concentrations and prolonged circulation in the bloodstream. 
4) Endocytosis into tumor cells facilitated by the EPR effect.
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3.1.1. Erythrocytes
Of all of the cell types used as membrane donors for NP func-
tionalization, the RBCs, also known as erythrocytes, are the 
most widely used. Mature RBCs do not contain a cell nucleus 
and lack internal organelles. Furthermore, the RBCs are natu-
rally able to remain in the bloodstream for ≈120 days and the 
membrane contains several “markers of self,” which inhibits 
immune activation responses.[92–94] Hence, RBCs make up a 
complex biological system that can be utilized for membrane 
donation for further functionalization of desired NPs, and they 
are abundantly present in a normal blood sample. Ghosts, a 
term describing the discoid bodies of RBCs after removal of 
hemoglobin, have been known since the 1960s[95] and the pro-
tocol has been further developed to be used for functionaliza-
tion of NPs.[55]
The use of plasmonic NPs for functionalization with cell 
membranes was first reported in 2013 by Gao et  al.[96] Here, 
AuNPs were used as carriers of RBC membranes. The ghosts 
from RBCs were extruded through 100 nm filters in a suspension 
with dispersed AuNPs to facilitate the fusion of membrane and 
particles. The functionalization was confirmed by transmission 
electron microscopy (TEM) as well as dynamic light scattering 
(DLS). Furthermore, the NPs were able to interact with anti-
bodies that are known to recognize the RBC exoplasmic protein 
CD47, thus confirming the functionalization of the RBC coating. 
To investigate the effect of the membrane coating on the stealth 
properties of the NPs, macrophage uptake was monitored after 
30 min of incubation with J774 murine macrophages, showing a 
significantly larger uptake of uncoated AuNPs.
Piao and Wang et al.[86] demonstrated that coating with RBC 
membranes prolongs the circulation time in mice compared 
to particles covered in a poly(vinylpyrrolidone) (PVP) coating, 
which has been proposed as a potential alternative to PEG.[69] 
They coated gold nano-cages (AuNCs) with RBC membrane 
and introduced the particles in mice for evaluation.[86] The 
particles retained the hollow core as well as porous structure, as 
confirmed by TEM. Furthermore, the particles did not change 
their plasmonic properties and no alterations of the UV–vis spec-
trum was observed after coating. The stealth properties of the 
membranes were shown by a lower amount of particles taken 
up by cells as well as by the biodistribution which suggested that 
the particles accumulate more at the tumor site and less in the 
major organs compared to PVP coated particles (see Figure 6).
In an effort to take advantage of the plasmonic properties 
of AuNPs, Ahn et  al. utilized AuNPs for X-ray imaging of the 
RBCs in the bloodstream.[98] Here, instead of coating the NPs 
with membranes, the AuNPs were incorporated into RBCs to 
be used as a contrast agent with X-ray imaging. By incubating 
the RBCs with AuNPs with different surface-chemistry under 
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Figure 5. Overview of viability and temperature increase after laser irradiation of membrane-coated NPs (or non-coated control NPs) inside tumor 
cells and inside mice inoculated with tumors. Data are taken and summarized from refs. [67,86–90] (ref. [91] is a part of the in vitro “coated particles” 
data; however, it only contains data from WBC-coated particles, but no control data). A) Viability of tumor cells obtained from six different studies 
based on laser treatment of tumor cells cultured with membrane coated plasmonic NPs (in the controls, the NPs were not membrane coated). Both 
the control and the coated particles were treated with NIR laser. It should be noted that one study uses PVP coated particles as a control[86] and that 
another study uses DOX without particles as control.[87] From the same study, the herein reported data demonstrate the viability of cells containing 
only coated nanocages, that is, without DOX. As a control for the CuNPs reported in ref. [90], NIR laser and DOX were used without particles. For 
the indocyanine + polymer study, a soy lecithin membrane was used for the control particles.[67] In summary, the data demonstrate that the viability 
of tumors containing coated nanoparticles is lower than the controls without. B) Temperature increase for different types of irradiated plasmonic NPs 
used for PTT. The type of NIR laser used in each study is stated above each particle type with the indicated wavelengths. Interestingly, the temperature 
increase in vivo is overall higher for the membrane-coated NPs. C) Images taken with a temperature-sensitive camera during PTT in mice using Fe3O4 
nanoclusters. Reproduced with permission.[89] Copyright 2016, Elsevier. The effect of membrane coating of the NPs is substantial compared to the 
controls. D) Quantification of the temperature data from experiments shown in (C). The fits are arbitrary and only have the purpose of visualizing the 
asymptotic tendency of the heating. Data are reproduced with permission from Ren et al.[89] The in vivo data shows a sharp increase followed by an 
asymptotic behavior and a clear positive effect of the membrane coating. E) Temperature increase in tumor tissue of mice using AuNCs. Reproduced 
with permission.[87] Copyright 2017, Wiley-VCH. Here, green dots signify the control without membrane coating; also in this experiment, membrane 
coating gives a clear positive effect on temperature increase.
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hypotonic conditions, the RBCs incorporated the particles, thus 
potentially enabling dynamic X-ray imaging of blood flow.
A combination of RBC and platelet membranes was used 
to create biomimetic NPs for biodetoxification and removal of 
pathogenic bacteria.[99] Due to the diverse interactions of bac-
teria and their subsequent hemolytic toxins with the human 
body, a NP bearing a multitude of biological functions was 
prepared from gold nanowires and the two different types 
of membrane.
The use of IONs in biomedicine has increased in recent years 
due to the large range of opportunities in biomedical applica-
tions.[100] In an attempt to create a biomimetic NP for combined 
MRI and PTT, Ren et al.[89] used magnetic nanoclusters which 
had already been shown to produce significant heating during 
laser irradiation at 808 nm.[52] The RBC-coated IONs showed an 
increased retention in the blood as well as improved cytotoxicity 
after laser irradiation in MCF-7 cancer cells. The biodistribu-
tion of the coated IONs were studied and showed an increased 
tumor accumulation as well as a lower percentage of particles 
localized in the spleen, liver, and kidney compared to bare IONs 
(see Figure 6). Furthermore, they were able to show a positive 
result after irradiation of tumors in mice. Here, it was found 
that the tumor growth was inhibited after laser irradiation of 
the coated NPs compared to mice without laser irradiation.
Another promising biomimetic nanoparticle was prepared 
by Rao et al.[88] By taking advantage of electroporation to create 
multiple membrane pores that small molecules and NPs can 
flow through, they were able to make a coating of RBC mem-
brane on the surface of IONs. The coated particles showed a 
significantly improved colloidal stability compared to bare 
IONs, indicating a surface functionalization that enhances 
stability, which is attributed to the hydrophilic glycans on the 
RBC surface. Following introduction of the particles to MCF-7 
cancer cells, it was obvious that the cytotoxic effect was signifi-
cant after laser irradiation with an 808 nm laser. Furthermore, 
the particles showed an increased blood retention as well as an 
ability to decrease tumor growth in mice.
As mentioned earlier, CuSNPs are capable of turning light 
into heat through the absorption of light at 900 nm.[48] It has 
been shown that CuSNPs can be coated with a hybrid mem-
brane of RBC membranes and cancer cell membranes (mela-
noma B16-F10 cells).[90] The particles showed an improved 
retention in the blood of mice indicating an effect from the 
membrane coating as well as an increased uptake in tumor 
tissue compared to bare NPs. For PTT, the NPs were incubated 
with B16-F10 cells and irradiated with a 1064 nm laser. This 
treatment showed a high cytotoxic effect compared to treat-
ments without the particles, and even treatment with DOX 
proved to be less effective than the PTT. The tumor repression 
was studied in mice, showing that the tumor progression was 
inhibited significantly when CuSNPs were irradiated with a 
1064 nm laser.
3.1.2. Leukocytes
WBCs, also known as leukocytes, are an interesting cell type 
to utilize as donor for NP coating. WBCs are a vital part of the 
human organism and the cells of the immune system. The 
cells are able to identify and eliminate pathogens and foreign 
substances in the body, thus being part of the primary defense 
system. Furthermore, WBCs are part of the repair process of 
damaged tissue.
WBC-coated particles were first reported in a study where 
three different types of leukocytes membranes (J774 macro-
phages, THP-1 monocytes, and Jurkat T lymphocytes) were 
coated onto 2.8 μm silica particles containing nanopores by 
Parodi et  al.[62] The coating of such particles significantly low-
ered the particle internalization compared with naked parti-
cles, especially when the investigated cell type matched the 
membrane coating. The membrane-coated particles were able 
to specifically bind to inflamed HUVEC endothelial cells due 
to a distribution of lymphocyte function-associated antigen 
1 (LFA-1) on the particles, which facilitated recognition of the 
LFA-1 receptor, ICAM-1, on the HUVEC cells. Furthermore, 
WBC membrane coated particles, loaded with DOX, were able 
to transport the drug through an endothelial cell layer and 
lower the viability of MDA-MB-231 cancer cells on the other 
side of the layer.
The use of WBC-coated NPs was further developed in 2017 
by Kang et al.[60] Neutrophils, which are the most abundant type 
of erythrocyte in the human body, were here used as donors 
for PLGA NPs. The coated particles showed a preference for 
the pre-metastatic site mimicked by HUVEC cells activated by 
TNF-α, with an almost threefold increase in NPs in the TNF-
α activated cells compared to non-treated cells. Inactivation of 
the LFA-1 receptor, ICAM-1, showed a significant decrease in 
associated particles, indicating that ICAM-1 signaling plays an 
important role in recruiting WBC membranes, and thus in 
recruitment of coated NPs. Furthermore, the WBC membrane 
coated NPs were introduced in a lung metastatic mouse model 
and demonstrated a better correlation between the coated NPs 
compared to the uncoated particles.
The publication by Xuan et  al.[91] is, to our knowledge, the 
only report containing data on plasmonic NPs coated with leu-
kocyte membranes. A coating on gold nanoshells (AuNS)s with 
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Figure 6. Overview of NP biodistribution and retention time in organs 
of mice using membrane coated NPs as well as un-coated control NPs. 
The biodistribution data are from refs. [67,86–91,97]. The retention time 
data are take from refs. [86,88,89,91,97]. A) Biodistribution of membrane-
coated NPs (red) and of control NPs (gray) 48 h after injection. This 
summary of biodistribution is based on seven studies involving photo-
activatable NPs. One of these studies uses PVP coating for controls 
both in vivo and in vitro.[86] Another study uses coated AuNS with DOX 
loading where the control is coated AuNS without DOX.[87] B) Retention 
in the bloodstream after 24 h. The retention in the blood is measured 
as %ID g-1. The plot is based on five different studies of membrane-
coated plasmonic NPs. One of these studies uses PVP-coated particles 
as a control.[86]
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macrophage membrane using the extrusion method showed 
a coating of the membrane on the particle, confirmed by a 
14 nm increase in particle size, measured with DLS. Using flow 
cytometry, it was shown that an internalization of particles in 
4T1 cancer cells was almost two times higher than when using 
bare NPs. Furthermore, the circulation time in mice increased 
and the accumulation at the tumor site increased. As a last 
test, mice were intravenously injected in the tail with AuNSs 
covered with WBC membranes followed by laser irradiation 
at 808 nm (1 W cm-2) for 5 min. The results showed a clear 
decrease of tumor growth, as opposed to an increase in all con-
trol groups. The possibilities with an assay taking advantage of 
the finely tuneable plasmonic properties of such particles and 
the clear targeting advantages of leukocyte membranes toward 
tumor cites can be of great importance for the future of PTT in 
cancer patients.
3.1.3. Cancer Cells
Cancer cell membranes have been given much attention due 
to the obvious importance of targeting cancer cells and the 
possibility of homotopic targeting.[65–67,87,90,97] PTT in cancer 
treatment has without a doubt received considerable attention 
through the last decades, owing to the targeting possibilities, 
the EPR effect, and the fact that a highly localized treatment 
is achievable. Several polymeric NPs have been coated with 
cell membranes from cancerous tissue,[65,66] and much effort 
has gone into functionalizing plasmonic particles with cancer 
cell membranes, copper NPs,[90] AuNCs,[87] and a plasmonic 
polymer.[67]
The photothermal properties of indocyanine green (ICG) 
was utilized for PTT by Chen et al.[67] By incorporating ICG into 
polymeric cores, NPs with plasmonic properties were obtained. 
The particles were functionalized with the membranes of 
MCF-7 cancer cells using standard coating method (detailed 
below) but in the presence of a PEG lipid (PEG-DSPE), the 
result being a polymeric plasmonic NP with a cancer cell cloak. 
The temperature increase following laser treatment was con-
firmed using infrared thermal imaging. The NPs showed a 
preference for MCF-7 cancer cells compared to other types of 
cancer and non-cancer cells. To evaluate the PTT possibilities, 
tumor-bearing mice treated with NPs were followed for 18 days 
without visible relapse of the tumor as opposed to the control.
Sun et  al. developed a multi-step mechanism for cancer 
therapy using AuNCs.[87] The first step involved incorporation 
of DOX for biochemical treatment of cancer and the second 
step was the coating of the AuNCs with membranes from 4T1 
cancer cells to target the tumor site. The AuNCs could then be 
used as drug carriers followed by PTT using a NIR laser. The 
results without laser treatment showed a lower cell viability 
when using DOX-loaded particles than pure DOX, which might 
be due to an increased uptake of membrane-coated particles 
by the cells. The viability dropped to almost zero as laser was 
applied, indicating that the PTT effect in combination with a 
high concentration of DOX was highly efficient for cancer 
treatment in vitro. In vivo studies further showed a significant 
decrease in tumor volume as the combination of DOX and PTT 
was used compared to either method alone.
In an effort to accommodate the need for in vivo highly spe-
cific tumor imaging methods, Rao et al. constructed a particle 
based on up-conversion nanoprobes.[97] Up-conversion nano-
probes are capable of converting NIR light to light in the visible 
region.[101] This, combined with a low cytotoxicity and the mem-
brane coating possibilities, makes the probes very interesting 
as imaging agents for cancer visualization. Vesicles derived 
from cancer cells by hypotonic treatment were mixed with the 
AuNCs followed by extrusion. The particles obtained showed 
an increased size and confirmation of a 9.8 nm membrane 
coat was shown using TEM. Imaging of the particles showed 
an increased signal at the tumor site, especially when using a 
membrane cloak equal to the type of tumor.
The specificity in targeting, as well as the promising results 
from combining drug loading and PTT, makes cancer cells a 
promising candidate for membrane coating donors and subse-
quent targeting and treatment.
3.1.4. Mesenchymal Stem Cells
The surface of mesenchymal stem cells (MSCs) expresses 
a multitude of receptors that can bind to tumor expressed 
ligands. This natural tumor homing ability can be exploited 
for drug delivery by using the stem cell membranes for coating 
NPs. MSCs additionally have a natural ability to evade the 
immune system which is a property expected to be inherited by 
the MSC membrane coated NPs. Furman et al.[83] demonstrated 
the efficiency of nanoghosts derived from MSC membranes for 
efficient targeting both in an in vitro and an in vivo system. The 
nanoghosts were additionally loaded with doxorubicin and led 
to an 80% inhibition of prostate cancer. Also, nanogels have 
been successfully coated with MSC membranes providing the 
NPs with tumor targeting ability and prolonging their circula-
tion time in vivo.[82] The hypo-immunogenicity combined with 
targeting property makes MSCs membranes highly attractive 
as a coating material in nanomedicine, but has yet to be 
thoroughly investigated for camouflaging plasmonic NPs.
3.2. Methods for Membrane Isolation and NP Coating
The coating of NPs using cell membranes involves mem-
brane isolation by various methods. The quality of the plasma 
membrane coating is imperative for establishing an efficient 
biointerface between the NP and immune cells, and hence the 
coating strategy needs attention to ensure functionality of the 
membrane and its embedded membrane proteins.
The coating strategy should ideally preserve the state of 
the native membrane, including all the protein parts which 
may constitute up to 50% fraction of the membrane area.[102] 
The complex mixture of lipids and proteins contained in 
the plasma membrane is apparently much more efficient 
in evading the immune system than simple lipid mixtures 
which have been used in liposome formulations for drug 
delivery during the last decade. This clearly shows that careful 
extraction of the plasma membrane from cells and proper NP 
coating are critical steps for achieving successful particles for 
drug delivery.
Adv. Optical Mater. 2020, 2000616
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As indicated in the previous section, the coating of NPs by 
membranes can be performed by several methods and these 
rely on physical and biochemical steps and depend on the type 
of cell used as a membrane donor.
Red blood cells are the simplest type of cells and can be 
hypotonically swollen and directly mixed with NPs, and by 
extrusion it is possible to achieve membrane coating.[2] The iso-
lation of RBC-membrane-derived vesicles involves centrifuga-
tion followed by hypotonic treatment for hemolysis followed by 
another centrifugation step to remove the hemoglobin to pro-
duce so-called ghosts.[55] This rather simple protocol makes it 
feasible for utilizing the RBC vesicles for NP camouflage for 
significantly prolonging the circulation time in the body.
In ref.  [88], the coating of magnetically active NPs by red 
blood cell membranes was improved by using a microfluidic 
device to mix NPs with hypotonically swollen red blood cells 
(see Figure 7). The RBC vesicles were mixed with IONS in a 
microfluidic chip followed by applying a pulsating electrical 
field, which facilitated the merging of IONs and RBC mem-
branes (see Figure 7).
Coating of NPs by membranes from more complex cell types 
like stem cells, cancer cells, or immune cells requires isolation 
of the cell membrane from other organelles prior to coating. 
This can be done by disruption of cells by hypotonic treatment 
followed by sonication and ultracentrifugation to facilitate iso-
lation of the membrane part, which then becomes a homog-
enized mass of lipids and membrane proteins.[83] Similar to the 
coating procedure with RBC membranes, the isolated mem-
brane mass can be extruded together with the NPs through 
narrow filters with slightly larger holes than the size of the NPs 
to be coated. This process has been proven to yield a mem-
brane layer on the NP, as shown by TEM images of stem cell 
membrane coated NPs[82] or macrophage-coated NPs[91] (see 
Figure 8).
The flexibility of the coating procedure of NPs is also dem-
onstrated by approaches which combine membranes from 
different cell types to form a hybrid coating on NPs. The RBC 
membrane can be fused to membranes from other cell types 
followed by coating of the NPs with the fused mixture. This 
approach was used in ref.  [90], where RBC membranes were 
isolated for further use and B16-F10 cell membranes were 
extracted using a membrane protein extraction kit. The two 
membranes were fused by sonication and the fusion was con-
firmed by Förster resonance energy transfer (FRET) between 
the mixed donor and acceptor fluorophores originating from the 
two membranes. The particle coating was simply achieved by 
sonication of a mixture of CuSNPs and RBC-B16 membranes.
3.3. Membrane Leaflet Orientation
The plasma membrane of cells contains highly organized and 
oriented proteins and a lipid asymmetry with most of the nega-
tively charged lipids residing on the inner leaflet. A loss of the 
natural membrane asymmetry can have functional implications 
if the membrane-coated NPs are supposed to mimic a natural 
membrane and hence avoid early clearance from the blood 
stream. Additionally, if homotypic targeting is used for, for 
example, cancer cell membranes, only receptors with the proper 
orientation will participate in recognition of specific moieties 
on the cancer cells. Orientation of the membrane cloak is there-
fore an important aspect to consider when coating NPs.
Characterization of the membrane coating remains poorly 
studied and most often the focus is on verifying that a mem-
brane layer of ≈ 10 nm thickness is in fact present on the NP 
surface, thus indicating successful membrane coating (see 
Figure 8). The crude isolation method for separating the lipid 
material from a cell, and the subsequent extrusion process, 
could result in a random orientation of the proteins within 
the plasma membrane coating. Further studies are needed to 
resolve the actual protein orientation within the NP coating and 
to assess the quality of the lipid bilayer, which could be filled 
with nanoscopic defects. Such studies would have the potential 
to further improve the effectiveness of membrane coatings in 
the targeting of NPs. Intriguingly, despite this lack of character-
ization, most studies report an impressive targeting efficiency 
and long circulation times when NPs are coated with mate-
rial from cellular plasma membranes,[82,83,91] thus indicating 
that membrane coating may constitute a robust stealth coating 
approach regardless of protein orientation. However, this could 
be optimized and a significant improvement of the aforemen-
tioned properties could be harvested.
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Figure 7. A microfluidic electroporation assay for efficient coating of nanoparticles with RBC membranes. A) Schematic showing the device consisting 
of an S-formed microfluidic channel with an electroporation device at the end of the channel. The combined microfluidic and electroporation device 
facilitates nanoparticle cloaking with RBC membranes by adding the vesicles and nanoparticles in two different inlets followed by thorough mixing 
in the S-shaped channel. The electroporation zone ensures pore formation in the RBCs which the nanoparticles can go through. B) Demonstration 
of the relative scale of the device. C) Calibration of the mixing efficiency of the two inlets as a function of time. D) Images from mixing of pure water 
with water containing a blue dye showing progressive mixing along the S-shaped channel. Reproduced with permission.[88] Copyright 2017, American 
Chemical Society.
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3.4. Giant Plasma Membrane Vesicles
Another strategy for isolating membranes has been to trigger 
vesiculation of cells, thus forming giant plasma membrane ves-
icles (GPMVs).[104,105] The GPMVs have been shown to contain 
the plasma membrane proteins from the donor cell with a cor-
rect orientation. Future work should exploit that these vesicles 
mimic the plasma membrane closely and experiments should 
be performed to see whether NP coating works by extruding 
or sonicating such vesicles in presence of NPs. It will be inter-
esting to see if the resulting membrane coating obtained by this 
method differs from the methods described above. The orien-
tation of membrane proteins can be tested by proteases which 
cleave off specific parts of the proteins which reside on the outer 
side of the membrane and hence are accessible to enzymes.[104]
Not all NPs may be suitable for membrane coating. Suc-
cessful coating of a bilayer membrane necessitates a hydro-
philic NP surface to allow for a thin hydration layer between 
the metal and the headgroups of the inner membrane leaflet. 
Coating of metallic NPs with a polymer cushion would ideally 
provide a water layer between the metal surface and the mem-
brane, thus facilitating fluidity of the membrane. Coating of 
flat surfaces like glass coverslips or mica surfaces with both 
artificial membranes and cellular plasma membranes is a well 
established technique.[106] This results in fluid membranes with 
a minor interaction with the substrate, which can be further 
minimized by tethering the bilayer to the substrate with either 
polymers[107] or other novel tethering strategies.[108] Whether 
a similar strategy is feasible for coating of NPs remains to 
be explored.
3.5. Characterization Issues
There is a huge lack of methods to characterize the biophys-
ical state of the coating membranes. Most studies rely on TEM 
imaging and DLS measurements to verify a diameter increase 
consistent with a membrane thickness. TEM imaging provides 
detailed information on the thickness of the electron-dense 
part of the NP coating. The lipid bilayer of cells is known to 
have a thickness of ≈5–6 nm and with an additional protein 
cloak, a somewhat thicker coating of 10 nm as detected by TEM 
imaging.[67,96,103] Drawbacks of using TEM imaging for charac-
terizing the NP coating include poor statistics due to single par-
ticle based quantification and, more importantly, the necessary 
dehydration of the sample may affect the membrane.
Dynamic light scattering allows for detection of the hydro-
dynamic diameter of NPs before and after coating in an 
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Figure 8. Characterization of membrane coating after coating of nanoparticles using red blood cell (RBC) membranes or plasma membranes isolated 
from cancer cells. A) Transmission electron microscopy (TEM) image of gold nanoparticles with a membrane cloak from RBCs. Reproduced with per-
mission.[96] Copyright 2013, Wiley-VCH. B) TEM image of polymeric indocyanine green loaded nanoparticles coated with a cell membrane from MCF-7 
cancer cells. Reproduced with permission. [67] Copyright 2016, American Chemical Society. C) TEM image of gold nanorods (AuNRs) coated with RBC 
membranes. D) Zeta potential measured for AuNRs with different types of surfactant coatings (CTAB: cetyl trimethyl ammonium bromide, SDS: sodium 
dodecyl sulfate, RBCM: red blood cell membrane) compared with zeta potential of intact RBC membranes. (C,D) Reproduced with permission.[103] 
Copyright 2018, Royal Society of Chemistry.
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aqueous environment, in contrast to TEM. The hydrodynamic 
diameter includes the particle, the protein coat, and possible 
additional polymeric extensions. Polymers extending from the 
membrane may be invisible by TEM, but contribute to the DLS-
measured diameter, which is based on diffusional properties of 
the particle.
Molecular packing of the membrane layer can be meas-
ured using environmentally sensitive probes like Laurdan or 
C-Laurdan, which both measure the extent of water penetra-
tion into the membrane.[105,109] Laurdan molecules intercalate 
between the lipids and the probe exhibits a red-shift upon con-
tact with water molecules. Hence, a red-shift of the Laurdan 
emission spectrum indicates a membrane with a more fluid 
character and thereby reports about the physical state of the 
membrane. Finally, calorimetry can be used to identify the 
actual transition temperature of both artificial and natural 
membranes.[110]
A physical characterization of membrane coating, which is 
possible using Laurdan probes or calorimetry, has so far not 
been applied to membrane coating of plasmonic nanoparticles. 
Future efforts should be made to compare the fluidity of NP 
coatings with cellular membranes. Notably, the extreme curva-
ture exhibited by the NP surface and the adhesion to the sur-
face may cause changes in the membrane as indicated by some 
studies.[111,112]
The orientation of the proteins embedded within the mem-
brane coating should also be assessed. This could, for example, 
be assessed by using proteases which can cleave off the pro-
tein part containing, for example, a fused green fluorescent 
protein (GFP).[104] The degree of loss of GFP signal indicates 
the fraction of proteins oriented toward the outer side of 
the membrane.
Other challenges in membrane coating assays include com-
plete removal of nucleic matter since genetic safety is essential 
when injecting material from cancer cells and stem cells into 
the blood stream. Such concerns can be alleviated by treating 
with RNases and DNases, thus preventing induction of malig-
nancies. Finally, upscaling and standardization of protocols will 
be critical for transition from lab bench to bedside for the ben-
efit of patients.
As a guide to the reader, we summarize in Table  1 the 
reported coatings of various NPs, including plasmonic and 
magnetic NPs, with associated references. Furthermore, the 
most significant advantages and disadvantages are listed in 
Table 2. The types of NPs explored with membrane coatings are 
rapidly expanding and the overview provided in Table  1 and 2 
does not provide a complete list of references.
4. Current and Future Challenges
If proper coating of NPs by intact plasma membranes can be 
achieved, we envision this technology has tremendous potential 
to be used for both hiding the NPs from the immune system 
while also providing efficient targeting. Clever approaches can 
combine the stealth technology provided by natural and bio-
mimetic membranes with genetic approaches to induce expres-
sion of specific cancer antigens or receptors. By genetically 
modifying donor cells to express both membrane receptors 
which can target cancer cells and proteins which convey a non-
threatening signal to the immune system, it will be possible to 
design very attractive membrane coated NPs for future drug 
delivery and for delivering functional plasmonic NPs for PTT. 
Harvesting intact plasma membranes from cells overexpressing 
either peripherally binding annexin proteins or transmembrane 
viral proteins has been demonstrated recently,[104] which should 
be extended to cells expressing relevant proteins for efficient 
targeting such as CD47.
Coating of NPs using other natural membranes like 
exosomes also provides efficient passivation of NPs in vivo.[116] 
Exosomes are small vesicles around 100–1000 nm in diam-
eter which are secreted from most cell lines and can easily be 
harvested by collecting the culturing medium containing the 
secreted vesicles. Exosome-coated NPs were recently prepared 
by a one-step method simply by sonication of the NP/exosome 
mixture.[116] Exosomes are naturally involved in cell–cell sign-
aling, and exosome membranes may therefore be very inter-
esting in terms of targeting NPs to specific tissues.
4.1. Future of Plasmonic Nanostructures
The thermoplasmonic properties of nanostructures have been 
extensively investigated and it is now possible to identify optical 
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Table 1. Overview of cell membrane coated nanoparticles of different 
types.
Cell type Particle type Ref.
RBC Polymeric* [55–58]
AuNPs† [96]
AuNPs‖† [98]
Au nanocages† [86]
Au nanorods† [103]
Fe3O4 NP‡† [88]
Fe3O4 nanoclusters‡† [89]
Melanin† [114]
RBC and platelets Au nanowires† [99]
RBC and cancer cells Copper sulfide nanoparticles† [90]
WBC Polymeric* [59–62]
Au nanoshells† [91]
Platelets Polymeric* [63]
Epithelial cells Polymeric* [64]
Cancer cells Au nanocages† [87]
Indocyanine green + polymer† [67]
Upconversion nanoprobes♭ [97]
Polymeric* [65, 66]
Myeloid-derived suppressor cells Fe3O4 NP‡† [115]
Bacteria AuNPs† [85]
RBC, red blood cells; WBC, white blood cells. The *symbol indicates PLGA, PLA, 
etc. The †symbol indicates plasmonic particles. The ‡symbol indicates Fe3O4, 
which has previously been shown to redshift the resonance peak of AuNP, if they 
are used as a coating.[113] The ♭symbol indicates fluorescent nanoprobes capable of 
converting NIR light to visible light[101] and finally, the ‖symbol indicates incorpora-
tion of the particle into cells.
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nanostructures for specific applications.[4] Some of the most 
efficient NIR absorbers include shells, rods, cubes, and stars 
made of gold. Also, other alternative materials exhibit high 
absorption in the NIR region as discussed in this review. As a 
guide to the reader, advantages and disadvantages of promising 
nanostructures are listed in Figure  3D. All structures listed 
in Figure  3D are made from gold; gold is an attractive mate-
rial because it is bio-compatible, non-toxic, and well suited for 
chemical conjugation. The structures with resonances that can 
be tuned into the NIR are especially attractive; the gold nanorod 
(AuNR) is an example of an NP with a high NIR absorption, 
a well-established chemical synthesis, commercial avail-
ability, and a favorable surface-to-volume ratio for drug con-
jugation. We envision that this nanostructure combined with 
camouflaging membrane-based strategies, as reviewed here, 
is an interesting candidate for future theranostic applications 
involving PTT.
However, plasmonic nanostructures also possess other 
attractive features when combined with thermoresponsive 
materials. Combining their efficient light-to-heat conversion 
with thermoresponsive membrane coatings adds another 
functionality to drug release controlled by irradiation.[117] For 
instance, gold nanostructures are well known to induce phase 
transitions and associated leakage in artificial membranes 
upon irradiation[36,118,119] and this property can be exploited in 
membrane-coated nanostructures. Gold nanocubes (AuNCs) 
are particularly interesting candidates in this context since they 
can be designed to exhibit NIR resonance and their hollow inte-
rior allows encapsulation of drugs. Combined with a thermore-
sponsive membrane coat with incorporated immuno-evasive 
peptides or proteins, AuNCs offer significant possibilities for 
tomorrow’s therapies.
4.2. Alternative Coatings
As described earlier, PEGylation has long been the preferred 
functionalization method of NPs for prolonging circulation 
time in the bloodstream. Using an approved standard chemical 
like PEG is desirable with respect to translation into clinical 
settings and in terms of commercial upscaling of NP produc-
tion. However, due to several problems arising from using this 
type of molecule,[69,73,74] a search for proteins involved with 
evading macrophage uptake has been of great importance. 
Future efforts should therefore uncover which components 
within the natural membrane are critical for the significant 
increase in circulation times observed for NPs coated with 
natural membranes. The integrin-associated protein, CD47, 
has a broad spectrum of functions as a cell surface receptor.[68]  
Of great importance, however, is the “do-no-eat-me” signal 
that it is able to pass on to macrophages upon binding to the 
signal-regulatory protein α on the macrophage membrane. 
The binding triggers a protein-binding cascade, resulting in 
inhibition of the Fcγ receptor-dependent endocytosis by mac-
rophages.[68,84] It is known that a functionalization method 
involving CD47 will help polystyrene particles evade phagocy-
tosis by certain macrophages, thus prolonging circulation in 
the bloodstream.[84] Recently, a peptide derived from CD47 was 
incorporated into artificial liposomes and resulted in significant 
inhibition of macrophage uptake[120](see Figure 9).
One favorable approach of protein functionalization of bio-
mimetic NPs is thus to facilitate evasion by identifying critical 
components of biological membranes, such as CD47, and incor-
porate these into the composition of a synthetic cloak used for 
coating plasmonic NPs. Furthermore, using synthetic lipids for 
the membrane coat can provide a future direction for industry-
scale production of membrane-coated NPs with purified com-
ponents from, for example, membranes from red blood cells, 
thus recapitulating the properties of the natural membranes. 
This could overcome the bottleneck of upscaling the production 
of native cell membranes and the inherent difficulty in stand-
ardizing and commercializing the production of membrane 
coats derived from living cells.
4.3. Effect of the Protein Corona
It is important to note that introduction of foreign objects, 
such as AuNPs, to the human body will cause a reaction. 
One of the very important aspects of this is the protein 
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Table 2. Overview of advantages and disadvantages of each type of membrane coating mentioned in Table 1.
Cell Type
RBC WBC Platelets Epithelial cells Cancer cells Mds. cells Bacteria
Advantages/ 
Disadvantages
Natural expression of ‘’do-not-eat-me signal’’ •
Prolongued blood retention • • • •
Reduced macrophage uptake • •
Nuclei-free cells • •
Abundant volumes in the blood • • •
Active targeting • • • • •
Facilitates homotypic targeting •
Immune activation •
Upscaling particle coating • • • • • • •
Standardization of particle coating • • • • • • •
RBC, red blood cells; WBC, white blood cells; Mds. cells, myeloid-derived supressor cells.
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corona formation on the surface of NPs introduced to the 
blood. NPs administered in vivo spontaneously and within 
minutes, acquire a protein corona, which consists of a com-
plex protein coat from blood components. This also applies 
to NPs coated with natural membranes and the effect of a 
protein corona on macrophage uptake should be investi-
gated. Several factors affect the formation of a corona, such 
as milieu, NP features (i.e., size, shape, and charge as well as 
functionalization by molecules/membrane), and conditions 
such as temperature, incubation period, and the timescale 
that the particles are circulating in the bloodstream.[121] 
Hadjidemetriou et al. found that the composition of proteins 
in the corona fluctuated over time and that the total amount 
of protein on the surface was more or less constant, indi-
cating a competitive nature of corona formation inside the 
bloodstream.[78] Interestingly, the protein adsorption on leu-
kosomes, which are bio-mimetic nanovesicles derived from 
leukocytes, were found to form less extensive protein corona 
compared to artificial liposomes, thus confirming the advan-
tages of nature’s own recipe for making bio-interfaces.[121] 
It is therefore important to be extra careful when drawing 
conclusions from in vitro experiments on NP uptake in cell 
cultures, since in vitro NPs are not exposed to the protein 
adsorption that occurs in the bloodstream, the flow changes, 
and possibly small changes in pH which are factors that may 
affect NP–cell interactions.
Finally, the effect of the membrane coating on the plasmonic 
properties of nanoparticles should be characterized. There is, 
however, evidence suggesting that membrane coatings, or other 
biological coatings, do not affect the plasmonic characteristics 
of NPs significantly. Cancer cell membrane coated AuNSs and 
ICG-polymeric core particles did not show any significant dif-
ference in the bulk light absorption capabilities.[67,87] Similar 
results were found for a variety of different RBC-coated nano-
particles[88–90,114] and macrophage-coated AuNSs.[91] This is not 
surprising since the membrane, or other types of organic mate-
rial, correspond to adding a very thin layer of dielectric mate-
rial to the NP and will therefore not change the Cabs. Biological 
material interacts poorly with the NIR wavelengths used in 
PTT,[122] and hence the plasmonic nanoparticles are expected 
to have a nearly identical plasmonic performance after addition 
of any type of biological coating. At lower wavelengths where 
absorption in biological material is higher, the membrane 
material could possibly interfere more with Cabs.[67,88]
4.4. Conclusion
The use of membrane-coated plasmonic nanoparticles is still in 
its infancy, but is quite promising due to the recently demon-
strated significant improvements in circulation time, biodistri-
bution, and therapeutic effect seen for a range of NPs coated 
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Figure 10. Proposed progress in the field of membrane-functionalized plasmonic nanoparticles for targeted photothermal therapy.
Figure 9. A liposome-based bio-inspired nanoparticle containing a CD47-derived peptide (D-self-peptide) on the surface. A) The peptide conveys a 
do-not-eat-me signal to macrophages, thus preventing initiation of phagocytosis. B) Uptake of conventional liposomes and D-self-peptide-labeled 
liposomes as a function of time, showing a dramatic inhibition of uptake caused by the peptide. Reproduced with permission.[120] Copyright 2019, 
American Chemical Society.
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with cell membranes from various cell types. We envision a 
productive line of development as depicted in Figure  10 over 
the next decade with improved standardization and upscaling 
methods for synthesizing efficient membrane-coated plasmonic 
and polymeric nanoparticles. Metallic and especially AuNPs 
exhibit a great potential in biomedical applications when com-
bined with cell membrane camouflaging as discussed in this 
review. It is important to mention that PTT using plasmonic 
nanoparticles can favorably be combined with other modes of 
interventions like immune-checkpoint inhibition,[123] which 
allows additional treatment of distant tumors. Importantly, the 
transition to clinical applications of plasmonic nanoparticles 
has already been demonstrated, as the first nanothermometry-
based clinical study in humans has proved that AuNSs are able 
to ablate prostate cancer tumors with low re-occurrence after 
12 months.[124] Also, the use of artificial biomimicking mem-
branes as coating of NPs will be a leap forward as it will facili-
tate production and upscaling as well as provide a uniform and 
reproducible high quality basis for clinical applications and 
commercialization. We foresee that if production of membrane-
coated nanoparticles can be upscaled, many successful clinical 
trials will be within reach in the near future.
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